Journal
VACCINE
Volume 27, Issue 50, Pages 7036-7045Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.09.066
Keywords
Leishmania; vaccination; MPL
Categories
Funding
- National Institutes of Health [A1025038, 31929, 42387]
- Bill & Melinda Gates Foundation
Ask authors/readers for more resources
Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available